30-working-day HSA approval, no regulatory review fees, zero GST on clinical trial materials, a multi-ethnic population representing three major Asian ancestries in one city, and Access Consortium membership.
Singapore is a sovereign city-state of just 733 km² at the southern tip of the Malay Peninsula; one of the world's smallest countries by area, yet one of its most economically powerful per capita (GDP per capita ~$88,000). Since independence in 1965, Singapore has transformed from a developing port city into one of the world's most advanced biomedical research hubs, anchored by government investment, a Singapore-style regulatory efficiency ethos, and a strategic position at the heart of Southeast Asia's 680 million people.
Clinical trials are regulated by the Health Sciences Authority (HSA), which consistently delivers Clinical Trial Authorisation (CTA) in 30 working days; making it one of the fastest regulators globally. Singapore is a member of the Access Consortium alongside Australia's TGA, Canada's Health Canada, Switzerland's Swissmedic, and the UK's MHRA; enabling work-sharing and mutual data reliance across five major pharmaceutical markets simultaneously. In April 2025, a new Mutual Recognition Agreement (MRA) between Singapore's five major IRBs eliminated the need for separate ethics approvals at each site for multi-centre studies.
Singapore's 6 million people; comprising 74% Chinese, 13% Malay, 9% Indian, and 4% other groups; represent an extraordinary concentration of three major Asian ancestries in a single, compact, highly educated, English-speaking location. This is Singapore's most distinctive asset in clinical research: a sponsor can conduct a single Phase I study in Singapore and obtain pharmacokinetic, pharmacodynamic, and safety data across Chinese, Malay, and Indian genetic backgrounds simultaneously; data that FDA and EMA explicitly consider more representative for drugs targeting global populations.
Singapore's universal healthcare system (MediShield Life, MediSave, MediFund) covers the entire resident population, and the country's high educational attainment, digital literacy, and trust in institutions contribute to excellent patient recruitment and protocol compliance rates.
The multi-ethnic advantage: Conducting ethnic sensitivity and pharmacogenomics studies in Singapore allows sponsors to obtain data on three major Asian ancestries simultaneously in one site; Chinese, Malay, and Indian. FDA and EMA view this far more favorably than three separate studies in three different Asian countries, and at a fraction of the coordination cost.
Singapore's appeal is built on regulatory speed, multi-ethnic diversity, intellectual property protection, and an exceptional quality of life that attracts and retains top international investigators. The government's S$50 million investment in precision oncology, the ClinicalTrials.SG national portal launched in 2024, and the SG100K/PRECISE population genomics project all signal a sustained national commitment to becoming Asia's premier clinical research destination.
30 working-day HSA CTA review; parallel IRB and HSA submission; April 2025 MRA between 5 major IRBs eliminates multi-site ethics duplication; Master Clinical Trial Agreement (MCTA) cuts contracting from months to weeks; zero regulatory review fees.
Zero HSA regulatory fees; zero GST on clinical trial materials imported for trials; no export license for biological samples; government R&D grants (A*STAR STDR); strong IP protection framework; lower cost than comparable Western quality markets.
6M people; three major Asian ancestries in one city-state; universal healthcare; English-speaking population; SG100K/PRECISE population genomics database; high trial participation culture; excellent protocol compliance and follow-up rates.
Access Consortium member; Phase I units at SGH, NUH, NCC, CGH; National Cancer Centre S$50M precision oncology investment; Duke-NUS, A*STAR, NUS academic ecosystem; 2024 ClinicalTrials.SG national portal; world-class biobank (SG100K).
Oncology is Singapore's leading therapeutic area, driven by strong government investment and the National Cancer Centre Singapore's active research program. Clinical pharmacology (particularly ethnic sensitivity and PK/PD studies) is a strategic focus reflecting Singapore's multi-ethnic population advantage. Gastroenterology/hepatology and cardiology round out the government-designated priority areas. Rare diseases and cell therapy are growing rapidly, supported by A*STAR's biomedical research programs.
Singapore's trials activity is concentrated across a small number of world-class institutions; all within the same city-state and collaborating through the CRIS (Consortium for Clinical Research and Innovation, Singapore) framework. The SingHealth cluster (SGH, NCC, KKH, CGH) and the NHG cluster (NUH, TTSH, NUHS) anchor the research ecosystem.
| # | Site | Cluster | Notes |
|---|---|---|---|
| 01 | National Cancer Centre Singapore (NCCS) | SingHealth | Singapore's dedicated national cancer center; Phase I–IV oncology specialist; S$50M precision oncology government investment; Duke-NUS partnership; HCC adjuvant therapy landmark trial; hematology, solid tumors, and immunotherapy. |
| 02 | Singapore General Hospital (SGH) | SingHealth | Singapore's largest hospital; broad Phase I–IV portfolio across oncology, cardiovascular, gastroenterology, and rare diseases; SingHealth Duke-NUS Academic Medical Centre; MRA IRB anchor; Duke-NUS Medical School partnership. |
| 03 | National University Hospital (NUH) | NUHS | National University Health System flagship; Phase I–IV across oncology, hematology, and rare diseases; NUS Yong Loo Lin School of Medicine partnership; National University Cancer Institute Singapore (NCIS) on campus; MRA IRB member. |
| 04 | Tan Tock Seng Hospital (TTSH) | NHG | NHG's anchor teaching hospital; infectious disease, respiratory, and cardiovascular trials; Lee Kong Chian School of Medicine (LKCMedicine) partnership; TTSH Research Office; active Phase II–IV commercial portfolio. |
| 05 | Changi General Hospital (CGH) | SingHealth | Clinical Trials and Research Unit (CTRU); Phase I specialist; 39+ industry-led Phase I studies since inception; PK/PD, ethnic sensitivity, and thorough QT studies; East Singapore patient population access; MRA IRB member. |
| 06 | Singapore General Hospital; Phase I Unit | SingHealth | Dedicated early-phase unit within SGH; oncology and non-oncology Phase I specialist; first-in-human studies; safety monitoring infrastructure; strong industry-sponsored Phase I portfolio. |
| 07 | KK Women's and Children's Hospital (KKH) | SingHealth | Women's and pediatric health specialist; Phase II–IV trials in maternal-infant health, pediatric oncology, and reproductive medicine; SingHealth Duke-NUS partnership; Asia's largest maternity hospital by deliveries. |
| 08 | National Heart Centre Singapore (NHCS) | SingHealth | Singapore's dedicated cardiovascular research center; Phase I–III cardiovascular trials; SingHealth Duke-NUS CVRI; access to Singapore's Asian cardiovascular disease profile (different risk factor mix to Western populations). |
| 09 | Ng Teng Fong General Hospital (NTFGH) | NUHS | Western Singapore anchor; Phase II–IV commercial portfolio; oncology, cardiovascular, and metabolic disease trials; NUHS West platform; growing clinical research infrastructure. |
| 10 | Alexandra Hospital | NUHS | Community hospital with growing research capacity; Phase II–IV observational and interventional studies; NUHS network access; serving Singapore's densely populated southern residential catchment. |
| 11 | National University Cancer Institute Singapore (NCIS) | NUHS | NUH's oncology research arm; Phase I–III across hematology, lymphoma, and solid tumors; PRL3-zumab Phase II (Singapore/US/China) landmark study; CSI Singapore partnership for translational research. |
| 12 | Institute of Mental Health (IMH) | NHG | Singapore's only specialty psychiatric hospital; CNS and psychiatric disorder trials; Phase II–III commercial portfolio; NHG Mental Health Research Department; unique access to Singapore's diverse psychiatric patient population. |
| 13 | Singapore Clinical Research Institute (SCRI) Coordinating Center | National | National academic CRO and coordinating body for Singapore's clinical trial strategy (CRIS); manages ClinicalTrials.SG portal; national trial coordinator support; SCRI Clinical Trials Symposium inaugural 2024; bridges all hospital clusters. |
Singapore's dedicated national cancer center; Phase I–IV oncology specialist; S$50M precision oncology government investment; Duke-NUS partnership; HCC adjuvant therapy landmark trial; hematology, solid tumors, and immunotherapy.
Singapore's largest hospital; broad Phase I–IV portfolio across oncology, cardiovascular, gastroenterology, and rare diseases; SingHealth Duke-NUS Academic Medical Centre; MRA IRB anchor; Duke-NUS Medical School partnership.
National University Health System flagship; Phase I–IV across oncology, hematology, and rare diseases; NUS Yong Loo Lin School of Medicine partnership; National University Cancer Institute Singapore (NCIS) on campus; MRA IRB member.
NHG's anchor teaching hospital; infectious disease, respiratory, and cardiovascular trials; Lee Kong Chian School of Medicine (LKCMedicine) partnership; TTSH Research Office; active Phase II–IV commercial portfolio.
Clinical Trials and Research Unit (CTRU); Phase I specialist; 39+ industry-led Phase I studies since inception; PK/PD, ethnic sensitivity, and thorough QT studies; East Singapore patient population access; MRA IRB member.
Dedicated early-phase unit within SGH; oncology and non-oncology Phase I specialist; first-in-human studies; safety monitoring infrastructure; strong industry-sponsored Phase I portfolio.
Women's and pediatric health specialist; Phase II–IV trials in maternal-infant health, pediatric oncology, and reproductive medicine; SingHealth Duke-NUS partnership; Asia's largest maternity hospital by deliveries.
Singapore's dedicated cardiovascular research center; Phase I–III cardiovascular trials; SingHealth Duke-NUS CVRI; access to Singapore's Asian cardiovascular disease profile (different risk factor mix to Western populations).
Western Singapore anchor; Phase II–IV commercial portfolio; oncology, cardiovascular, and metabolic disease trials; NUHS West platform; growing clinical research infrastructure.
Community hospital with growing research capacity; Phase II–IV observational and interventional studies; NUHS network access; serving Singapore's densely populated southern residential catchment.
NUH's oncology research arm; Phase I–III across hematology, lymphoma, and solid tumors; PRL3-zumab Phase II (Singapore/US/China) landmark study; CSI Singapore partnership for translational research.
Singapore's only specialty psychiatric hospital; CNS and psychiatric disorder trials; Phase II–III commercial portfolio; NHG Mental Health Research Department; unique access to Singapore's diverse psychiatric patient population.
National academic CRO and coordinating body for Singapore's clinical trial strategy (CRIS); manages ClinicalTrials.SG portal; national trial coordinator support; SCRI Clinical Trials Symposium inaugural 2024; bridges all hospital clusters.
These are the primary regulatory, academic, and industry bodies shaping Singapore's clinical research ecosystem.
National regulator; 30 working-day CTA review; zero regulatory review fees; Access Consortium member; ICH-GCP aligned; CTN and CTC pathways; parallel IRB/HSA submission; export license not required for biological samples.
Government research agency; Singapore Therapeutics Development Review (STDR) grants; Genome Institute of Singapore (GIS); SG100K/PRECISE population genomics project; biomedical research ecosystem anchor.
National coordinating body implementing Singapore's clinical trial strategy; oversees SCRI; ClinicalTrials.SG portal; bridges academic clusters, HSA, and industry sponsors; launched by Deputy Prime Minister July 2024.
Singapore's leading research medical school (Duke-NUS partnership); oncology, cardiovascular, and neuroscience specialty; SingHealth Duke-NUS Academic Medical Centre; international clinical trial collaborations.
National academic CRO; established 2008; appointed national coordinating body 2021; SCRI Symposium 2024; ClinicalTrials.SG; coordinator support for all HSA-registered trials; CRIS member.
SG100K population genomics project; 100,000 Singaporeans genotyped; multi-ancestry reference database; clinical trial feasibility and patient stratification; world-class biobank.
Asia-Pacific regional headquarters; full Phase I–IV management; HSA regulatory expertise; site network across all SingHealth and NHG clusters; data analytics and real-world evidence.
Asia-Pacific operations; clinical operations, site management, and regulatory submissions; pan-APAC trial coordination; specialist in multi-ethnic Phase I pharmacology studies.
Global CRO with APAC headquarters in Singapore; HSA regulatory expertise; oncology and rare disease specialty; serves as regional trial management hub for Southeast Asian programs.
Singapore is one of Asia's most efficient clinical research markets and a particularly strong setting for early phase, multi ethnic pharmacology studies. No regulatory review fees, zero GST on IMP imports, 30 working-day CTA approval, a 2025 multi-IRB MRA eliminating multi-site ethics duplication, and Access Consortium membership making data simultaneously acceptable to Australia, Canada, Switzerland, and the UK. The city's roughly 6.1 million residents include Chinese, Malay, and Indian ancestry groups in one compact location; enabling ethnic sensitivity studies that FDA and EMA find uniquely compelling. For any sponsor building an APAC clinical development strategy, Singapore is not just a starting point. It is the command centre.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.